PRQR
ProQR Therapeutics N.V.
$1.44
0.00%
$151.7M
No data for this timeframe.
Vol
Market Cap$151.7M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (93%)
Reddit Sentiment75° Bullish
SEC Reports5
Press Releases4
Recent Activity
Jun 2, 2026
SEC
ProQR Therapeutics filed a 6-K reporting the results of its 2026 annual general meeting of shareholders held on June 2,
6-K — Impact 2/10
Jun 2, 2026
Insider
Hinsch Gylvin Lykke was granted 14,495 shares
Director
Jun 2, 2026
short_volume
Short Volume: PRQR — 58.5% short (0.4M / 0.7M)
Short: 426,577 | Exempt: 67,940 | TRF Vol: 728,800 | Short Ratio: 58.5% | Off-exchange volume (dark
May 12, 2026
SEC
ProQR reported Q1 2026 results with revenue declining 55% YoY to €2.0M and net loss widening 33% to €13.4M (€0.13/share)
6-K — Impact 6/10
Apr 30, 2026
SEC
ProQR announced the nomination of Dr. Lykke Hinsch Gylvin, CMO of Boehringer Ingelheim, to its Board of Directors, subje
6-K — Impact 2/10
Apr 30, 2026
Press
ProQR announced the nomination of Lykke Hinsch Gylvin, MD, EMBA, Chief Medical Officer and Head of Global Medicine at Bo
Impact 2/10
Apr 8, 2026
Press
ProQR Therapeutics provided a pipeline update highlighting progress on its lead program AX-0810, with target engagement
Impact 4/10
Price Targets
$8.88
+516.3% upside
Strong Buy
Current $1.44
Low $4.00
Median $8.50
High $14.00
8 analysts
$4.00
$14.00
Analyst Ratings
5Strong Buy
9Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 9, 2026 | Chardan Capital | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.19 | $-0.19 — $-0.19 | 1 | |
| Next Q | $-0.14 | $-0.14 — $-0.14 | -15% YoY | 1 |
| Current FY | $-0.62 | $-0.62 — $-0.62 | 1 | |
| Next FY | $-0.68 | $-0.68 — $-0.68 | -10% YoY | 1 |
Latest Reports
NEUTRAL
6-K
2/10
ProQR Therapeutics filed a 6-K reporting the results of its 2026 annual general meeting of shareholders held on June 2,
Jun 2, 2026
BEARISH
6-K
6/10
ProQR reported Q1 2026 results with revenue declining 55% YoY to €2.0M and net loss widening 33% to €13.4M (€0.13/share)
May 12, 2026
NEUTRAL
Press
2/10
ProQR announced the nomination of Lykke Hinsch Gylvin, MD, EMBA, Chief Medical Officer and Head of Global Medicine at Bo
Apr 30, 2026
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 2, 2026 | Hinsch Gylvin | A | $0.00 |
Reddit Sentiment
75°
Bullish
Bearish
Neutral
Bullish
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
1 unique insiders with 1 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 2, 2026 | Hinsch Gylvin Lykke | Director | AWARD | 14,495 | — | — |
5 SEC filing reports analyzed. Sentiment: 2 bullish, 1 bearish, 0 mixed, 2 neutral. Avg impact: 4.6/10.
NEUTRAL
6-K
2/10
ProQR Therapeutics filed a 6-K reporting the results of its 2026 annual general meeting of sharehold
Jun 2, 2026
BEARISH
6-K
6/10
ProQR reported Q1 2026 results with revenue declining 55% YoY to €2.0M and net loss widening 33% to
May 12, 2026
NEUTRAL
6-K
2/10
ProQR announced the nomination of Dr. Lykke Hinsch Gylvin, CMO of Boehringer Ingelheim, to its Board
Apr 30, 2026
BULLISH
6-K
6/10
ProQR Therapeutics announced pipeline expansion and upcoming clinical catalysts at an investor event
Apr 8, 2026
BULLISH
6-K
7/10
ProQR Therapeutics announced a strategic partnership with Ginkgo Bioworks to enhance its AI-driven d
Apr 8, 2026
NEUTRAL
2/10
ProQR announced the nomination of Lykke Hinsch Gylvin, MD, EMBA, Chief Medical Officer and Head of G
Apr 30, 2026
NEUTRAL
4/10
ProQR Therapeutics provided a pipeline update highlighting progress on its lead program AX-0810, wit
Apr 8, 2026
MIXED
6/10
ProQR Therapeutics reported its 2025 financial results and provided a business update, highlighting
Mar 12, 2026
NEUTRAL
3/10
ProQR Therapeutics announced that its management will present at the Citizens Life Sciences Conferen
Mar 3, 2026
Current analyst consensus: Strong Buy (93% buy). Based on 15 analysts: 5 strong buy, 9 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$8.88 mean target
+516.3% upside
Strong Buy (1.13)
$4.00 Low
$14.00 High
| Metric | Value |
|---|---|
| Current Price | $1.44 |
| Target Low | $4.00 |
| Target Mean | $8.88 |
| Target Median | $8.50 |
| Target High | $14.00 |
| # Analysts | 8 |
| Recommendation | Strong Buy (1.13) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.19 | $-0.19 | $-0.19 | — | — | — | $0.0B | 15.7% | 1 |
| Next Q 2026-09-30 |
$-0.14 | $-0.14 | $-0.14 | -15.3% | — | — | $0.0B | 59.3% | 1 |
| Current FY 2026-12-31 |
$-0.62 | $-0.62 | $-0.62 | — | — | 0↑ 1↓ | $0.0B | -17.9% | 1 |
| Next FY 2027-12-31 |
$-0.68 | $-0.68 | $-0.68 | -10.2% | — | 0↑ 1↓ | $0.0B | 7.0% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.186 | |
| 7d ago | $-0.176 | -0.010 |
| 30d ago | $0.000 | -0.186 |
| 60d ago | $0.000 | -0.186 |
| 90d ago | $0.000 | -0.186 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 9, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 5 | 9 | 1 | 0 | 0 | 93% | |
| May 1, 2026 | 5 | 9 | 1 | 0 | 0 | 93% | |
| Apr 1, 2026 | 5 | 9 | 1 | 0 | 0 | 93% | |
| Mar 1, 2026 | 5 | 9 | 1 | 0 | 0 | 93% | |
| Feb 1, 2026 | 5 | 9 | 1 | 0 | 0 | 93% | |
| Jan 1, 2026 | 5 | 9 | 1 | 0 | 0 | 93% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
75°
Bullish
Bearish
Neutral
Bullish
4 mentions
4 bullish
0 bearish
4 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 12, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 12, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 29, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 29, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
Jun 2, 2026
short_volume
Short Volume: PRQR — 58.5% short (0.4M / 0.7M)
Short: 426,577 | Exempt: 67,940 | TRF Vol: 728,800 | Short Ratio: 58.5% | Off-exchange volume (dark pool + OTC)
May 6, 2026
earnings_calendar
PRQR Q1 2026 Earnings Scheduled — 2026-05-06
Apr 30, 2026
announcement
ProQR Announces Nomination of Dr. Lykke Hinsch Gylvin to its Board of Directors
<p>LEIDEN, Netherlands & CAMBRIDGE, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage c
Apr 30, 2026
earnings_calendar
PRQR Q1 2026 Earnings Scheduled — 2026-04-30
Apr 8, 2026
announcement
ProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst Event
<p>LEIDEN, Netherlands & CAMBRIDGE, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicat
Mar 30, 2026
short_volume
Short Volume: PRQR — 61.3% short (0.5M / 0.7M)
Short: 458,041 | Exempt: 43,930 | TRF Vol: 746,651 | Short Ratio: 61.3% | Off-exchange volume (dark pool + OTC)
Mar 12, 2026
announcement
ProQR Announces Year End 2025 Operating and Financial Results
<p>LEIDEN, Netherlands & CAMBRIDGE, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicate
Mar 3, 2026
announcement
ProQR Announces Webcast of Presentation at the 2026 Citizens Life Sciences Conference
<p>LEIDEN, Netherlands & CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicate